Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab-Reference-Cited by-同舟云学术

Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab

Published:2023-10-27 Issue:1 Volume:30 Page:131-133
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Beigneux Ysoline¹^ORCID,Louapre Celine¹,Bihan Kevin²,Roux Thomas¹^ORCID,de Paz Raphael¹,Lubetzki Catherine¹,Maillart Elisabeth¹^ORCID

Affiliation:

1. Sorbonne University, Paris Brain Institute – ICM, Assistance Publique Hôpitaux de Paris, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France

2. Department of Pharmacology, Regional Pharmacovigilance Center, Sorbonne Université, AP-HP. Sorbonne Université, Pitié-Salpêtrière Hospital, INSERM, Paris, France

Abstract

Background: Late-onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1500/mm3 that develops between 4 weeks and 6 months after the last drug administration, is a rare side effect of anti-CD20 drugs including ocrelizumab. Although continuation of ocrelizumab after LON is not contraindicated, the risk of LON recurrence is not well known. Cases: We report three cases of recurrent symptomatic agranulocytosis (ANC < 500/mm3) occurring under ocrelizumab. Conclusion: Given the risk of recurrence of symptomatic agranulocytosis and the availability of other treatments, a therapeutic switch may be discussed after the first episode of LON.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585231206218

Reference10 articles.

1. Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study

2. Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease

3. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas

4. Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma

5. Late-onset neutropenia following anti-CD20 therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: A report on two patients

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2024-08-03

2. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18